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Neurodevelopmental disorders are classified as diseases that cause abnormal functions of the brain or central
nervous system. Children with neurodevelopmental disorders show impaired language and speech abilities,
learning and memory damage, and poor motor skills. However, we still know very little about the molecular
etiology of these disorders. Recent evidence implicates the bromodomain-containing proteins (BCPs) in the
initiation and development of neurodevelopmental disorders. BCPs have a particular domain, the bromodomain
(Brd), which was originally identified as specifically binding acetyl-lysine residues at the N-terminus of histone
proteins in vitro and in vivo. Other domains of BCPs are responsible for binding partner proteins to form regulatory
complexes. Once these complexes are assembled, BCPs alter chromosomal states and regulate gene expression.
Some BCP complexes bind nucleosomes, are involved in basal transcription regulation, and influence the
transcription of many genes. However, most BCPs are involved in targeting. For example, some BCPs function as a
recruitment platform or scaffold through their Brds-binding targeting sites. Others are recruited to form a complex
to bind the targeting sites of their partners. The regulation mediated by these proteins is especially critical during
normal and abnormal development. Mutant BCPs or dysfunctional BCP-containing complexes are implicated in the
initiation and development of neurodevelopmental disorders. However, the pathogenic molecular mechanisms are
not fully understood. In this review, we focus on the roles of regulatory BCPs associated with neurodevelopmental
disorders, including mental retardation, Fragile X syndrome (FRX), Williams syndrome (WS), Rett syndrome and
Rubinstein-Taybi syndrome (RTS). A better understanding of the molecular pathogenesis, based upon the roles of
BCPs, will lead to screening of targets for the treatment of neurodevelopmental disorders.
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Neurodevelopmental disorders are complicated diseases.
Studies are currently underway to understand their regu-
latory mechanisms, to explore better treatments and, ul-
timately, to prevent their onset.
Chromatin modification traits are associated with the
pathogenic characteristics of many neurodevelopmental
disorders. Bromodomain-containing proteins (BCPs),
which contain a bromodomain (Brd), represent a family* Correspondence: xcgao@nwu.edu.cn
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reproduction in any medium, provided the orof proteins found in many chromatin-associated proteins
and in a range of transcription factors. A hydrophobic
pocket formed by the ZA loop and BC loop is respon-
sible for acetyl-lysine recognition and specific binding,
the accuracy of which could be improved by sequence
and acetyl-lysine modification of target sites. Thus, sev-
eral inhibitors targeting these interactions have been
designed for potential clinical application.
BCPs play pivotal roles in transcription regulation.
Some BCPs participate in initiation and regulation of
basal transcription by binding nucleosomes. However, as
targeting proteins, some BCPs can recruit their binding
substrates and bind their target through the Brds as the
‘reader’ or a recruitment platform for modular protein
complexes. They regulate gene transcription by bothhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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recruited by other transcription factors (such as p53),
and function as modifying enzymes. Consequently, this
affects the transcription of downstream genes of other
transcription factors.
Abnormal BCPs or BCP-containing complexes in the
nervous system have been shown to cause neurode-
velopmental disorders, including neural tube defects (for
example, GCN5 or BRD2), mental retardation (for ex-
ample, BRWD3), Williams syndrome (WS; for example,
BAZ1B), Rett syndrome (for example, SWI/SNF), Rett
syndrome and Rubinstein-Taybi syndrome (RTS; for
example, CBP/p300), and Fragile X syndrome (FRX; for
example, CBP/p300).
Although the available inhibitors are not efficient
enough to be used clinically, for example, by simply
increasing histone acetyltransferase (HAT) activity, re-
cent evidence has provided the starting point to investi-
gate BCP’s role in nervous system development and
neurodevelopmental disorders.
Introduction
Neurodevelopmental disorders are a group of diseases
characterized by impairment of the growth and develop-
ment of the brain or central nervous system. Most
neurodevelopmental disorders affect behavior, resulting
in economic and mental problems, not only for the
patients, but also for their families and society. The most
common forms of these disorders include mental retard-
ation, autism, bipolar disorder, schizophrenia, attention-
deficit/hyperactivity disorder, and learning and memory
impairment [1,2].
Understanding the regulatory mechanisms of these
diseases is vital for developing better treatments and for
preventing their onset. Neurodevelopmental disorders
are thought to be caused by (a combination of ) genetic
and environmental factors. Epigenetic modification is
affected by environmental factors, such as drugs, nutri-
tion, toxicities, and mental stress, and its traits are in line
with the pathogenic characteristics of neurodevelopmental
disorders. Epigenetic modification of chromatin provides a
dynamic platform for regulating the expression of target
genes via acetylation, phosphorylation, methylation, ubi-
quitination, and sumoylation [3]. Among such intricate
regulatory mechanisms, the equilibrium between global
histone N-terminal deacetylation and acetylation changes
in response to environmental stimulation through the func-
tional interplay between HATs and histone deacetylases
(HDACs). When the equilibrium is disturbed in the brain
or central nervous system, patients develop neurode-
velopmental disorders with complicated phenotypes.
In the present review, we focus on the roles of BCPs
in the pathogenesis of neurodevelopmental disorders.
BCPs represent a family of proteins found in manychromatin-associated proteins or in nearly all known nu-
clear HATs, and contain particular Brds. The importance
of BCPs is underscored by the fact that genetic
alterations of these genes and the subtle balance of
aberrant acetylation are strongly linked to complicated
diseases, such as cancer and neurodevelopmental dis-
orders (Table 1). Here, we focus on the key advances in
the current understanding of BCPs in the pathogenesis
of neurodevelopmental disorders [4]. Special attention is
paid to FRX, WS and RTS.
Background of BCPs
The Brd, first identified in the Drosophila brahma
(BRM) protein, is a highly evolutionarily conserved do-
main. More than 75 human BCPs have been identified
in the National Center for Biotechnology Information
(NCBI) protein database using Brd sequences as query
sequences [20,21]. With their particular domains and
special functions, BCPs have been identified in a number
of nuclear proteins, such as methyltransferases (for ex-
ample, Ash1 and MLL) and HATs (for example, GCN5
and PCAF), as constituents of chromatin-remodeling
complexes (for example, BAZ1A and BAZ1B) and in
transcription factors (TFs) (for example, BRD1-4 and
BRWD3). Here, we briefly introduce the structure and
functions of BCPs, and their relevance to the pathogen-
esis of neurodevelopmental disorders.
The spatial structure of Brd results in recognition and
binding of target regions. Other critical domains in
BCPs, the amino acid sequences and posttranslational
modifications of target sites combine to subtly and
accurately regulate both the chromatin state and the
transcription of target genes.
Originally, Brd was described as an approximately 60
amino acid domain forming two α-helices. After analyz-
ing the Brds of several BCPs, Jeanmougin et al. identi-
fied a larger domain of about 110 residues [22]. Based
on the resolved structure of Polybromo BRG1-associated
factor (PCAF), a typical Brd forms an atypical left-
handed, four-helix bundle topology, which includes A, B,
Z, and C helixes paired in loops. A hydrophobic pocket
formed by a combination of the Z-A loop with the B-C
loop is responsible for acetyl-lysine recognition and
specific binding [23,24]. Brds may exist at the N- or C-
terminus or in the center of proteins, with a repeat
number varying from one to six (Figure 1). It is not clear
whether the repeated Brds within a protein bind differ-
ent targets or are a product of natural redundancy. One
possible explanation is that the other Brds bind different
specific substrates as integration platforms, or allocate
the proteins to different nuclear compartments. Self-
dimerization of some Brds plays a crucial role in their
binding capacity. Using structural data, Nakamura et al.
determined that Brd1 of BRD2 forms an intact homodimer,
Table 1 BCPs implicated in neurodevelopmental disorders
Protein Name Alias BRDs Protein functions Neurodevelopmental
disorders
Reference




1 Chromatin remodeling factor Williams syndrome [5,6]
BAZ1B Bromodomain adjacent to zinc finger
domain, 1B
WSTF, WBSCR9 1 Chromatin remodeling factor,
transcriptional regulator
Williams syndrome [6,7]





BRD3 Bromodomain-containing protein 3 ORFX, RING3L 2 Transcription factor Autism spectrum
disorder
[9,10]
BRWD3 Bromodomain and WD repeat-containing
protein 3
BRODL 2 Transcription factor Mental retardation [11,12]
CECR2 Cat eye syndrome critical region 2 1 Chromatin remodeling factor Anencephaly [13]





EP300 E1A-binding protein p300 p300, KAT3B 1 HAT Rubinstein-Taybi
syndrome 2
[15]
GCN5L2 General control of amino acid synthesis
5-like 2
KAT2A, GCN5 1 HAT Neural tube defects [16]
SMARCA2 SWI/SNF-related matrix associated anti-
dependent regulator of chromatin a2
BRM, SNF2L2 1 Chromatin remodeling factor Nicolaides-Baraitser
syndrome
[17]
SMARCA4 SWI/SNF-related matrix associated actin-
dependent regulator of chromatin a4
BRG1, SNF2L4,
SNF2LB
1 Chromatin remodeling factor Mental retardation [18]
TAF1 TAF1 RNA polymerase II, TATA
box-binding protein (TBP)-associated factor
TAFII250 2 Transcription initiation X-linked dystonia-
parkinsonism
[19]
BCPs, bromodomain-containing proteins; BRDs, bromodomains.
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acetylated H4K12, whereas the dimer interface of Brd1
binds to hypoacetylated H4K8 [25]. Brd2 of BRD2 is
monomeric in solution. The affinity between Brd2 of
BRD2 and the acetylated H4K12 peptide is as low as 2.9
mM. This implies that BRD2 Brd1 and Brd2 have distinct
roles in BRD2’s function [26]. Other BCPs can form
dimers, including BRD4, TFIID, TAF1, and BRDT. Self-
dimerization may help to avoid erasing histone codesFigure 1 Bar diagram of representative BCPs and their major associat
(1 and 2); BAZ1, bromodomain adjacent to zinc finger domain; BCPs, brom
regions (1, 2 and 3); CTK, C-terminal kinase domain; DDT, DNA binding hom
/conjugating domain; HAT, histone acetyltransferase domain; HMG, high-m
kinase domain; WAC, WSTF/Acf1/cbp146; WD, tryptophan-aspartic acid dipduring mitosis [27] or might improve modification accur-
acy [28].
Brds can specifically bind target sites, and the other
domains in BCPs contribute to recruit partner proteins or
play other critical roles. For example, in p300/CBP, these
other domains include three cysteine-histidine (CH) rich
domains (CH1, CH2, and CH3), a KIX domain, and an
ADA2-homology domain (Figure 1). In particular, both the
PHD finger and Brd of p300 are required for interactioned domains. ADA2, adaptor 2; BAH, bromo-adjacent homology
odomain-containing proteins; Brd, bromodomain; C/H, Cys/His rich
eobox and different transcription factors; E1/E2, ubiquitin-activating
obility group domain; LH, leucine-rich helical domain; NTK, N-terminal
eptide domain.
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in an acetylation-dependent manner when the PHD finger
is combined with Brd. When both of these domains are
isolated, the PHD finger binds to nucleosomes in an
acetylation-independent manner, while the isolated Brd
cannot bind nucleosomes at all [29,30]. What is the rela-
tionship between Brd and PHD in p300? Increasing evi-
dence shows that they form a cassette in BPTF, MLL, and
TRIM24 proteins. The MLL PHD domain binds methy-
lated H3K4 and Brd [31,32]. PHD fingers not only recog-
nize an acetyl-lysine residue of histone tails, as does Brd,
but also recognize a wide variety of peptides, either modi-
fied by methylation, acetylation, or unmodified [32-34].
Complexes containing BCPs subtly and accurately
regulate transcription through substrate recognition and
by selecting and coordinating between Brds and other
domains of BCPs. Brds specifically bind acetylated lysine
residues, and the amino acid sequence surrounding the
target site is also important for their binding ability
[24,35]. Significantly, a recent study showed that the
flanking posttranslational modifications on targeting
sites, such as phosphorylation and acetylation, are
critical for Brds’ specific recognition and binding of
substrates [33]. For Brds and other domains of BCPs, re-
cent studies showed their combination improved the ac-
curacy of the regulatory roles of BCPs. In p300, the Brd
is important in maintaining the basal activity of HATs
and in inducing transcription of the target genes [36].
Ivanov et al. uncovered an interaction between the PHD
domain and Brd, where the PHD domain of the KAPI
corepressor functions as an intramolecular E3 ligase for
sumoylation of the adjacent Brd [37]. Based on the
spatial reorganization and binding between Brds and
their substrates, various inhibitors have been identified
as specifically antagonizing the interaction between
acetylated histones and Brds. These inhibitors include
ischemin [38], novel benzodiazepines, benzotriazepine
[39], and I-BET (a derivative of benzodiazepine) [40].
These inhibitory benzodiazepines have anti-inflammatory
effects, and have potential benefits for treating specific
carcinomas [41-43]. The results from inhibitor studies
suggest the important roles of the fine regulation mechan-
ism during normal and abnormal development. More
detailed regulatory information, novel targets, and new
inhibitors represent promising strategies towards delaying
or halting the progression of neurological disorders.
BCPs have multiple functions that rely on particular
domains that modify or recruit proteins to form
regulatory complexes in response to developmental
and environmental cues.
BCPs are implicated in the regulation of cellular
events, including the cell cycle, growth, proliferation,differentiation, and apoptosis. Deletion models of differ-
ent BCPs show a wide range of effects, such as lethality,
slow growth, or no phenotypic change [44].
BCPs were initially considered as activators. The tran-
scriptional coactivators CBP/p300, key members of the
BCP family, participate in RNA polymerase II-mediated
transcription. CBP/p300 possesses HAT activity and
transfers an acetyl group from acetyl coenzyme A to a
recipient lysine residue. Thus, CBP/p300 loosens dense
chromatin, influences global chromatin acetylation and
subsequently regulates transcription [45,46]. The binding
between p300 and its target gene promoters provides an
accessible chromatin structure directly. Indirectly, an-
other key property of CBP/p300 is as a protein bridge,
providing a platform for other BCPs and transcriptional
regulators [47]. A number of proteins bind to CBP/p300
through the CH1, CH3, and the KIX domains, which are
important in mediating protein interactions and in the
regulation of cellular events. The interaction between
CBP/p300 and E1A is important in cell cycle regulation,
involving the control of DNA synthesis and S phase pro-
gression, whereas the CBP/p300-p53 interaction is
involved in cell apoptosis. The transactivation activity of
p53 is improved after acetylation by CBP/p300, which is
accompanied by a concomitant increase of the half-life
of p53. After DNA damage, p53 might be acetylated by
CBP through the Brd binding lysine 382-acetylated p53
peptide. Transcription of cyclin-dependent kinase inhibi-
tor p21 is then activated to induce cell cycle arrest, sen-
escence, or apoptosis. In this process, CBP acts as a
HAT and regulates the transcription of p53 downstream
genes through p53 binding target sites [48].
Accumulating evidence suggests that the same BCP
would function as an activator or a repressor in different
situations. For example, BRD7 is a component of
chromatin-remodeling complexes, acting as either an
activator or an inhibitor. The complex consisting of
BRD7 and interferon regulatory factor 2 in the nucleus
may activate chromatin transcription in situ. In the case
of breast cancer with wild-type p53 and deletion of
BRD7, the latter has been suggested as a cofactor in the
transcriptional regulation of p53 target genes. In the
complex constituted by BRD7 and p53, BRD7 affects
p53 acetylation and the promoter activity of p53 target
genes [49]. In the animal model, when GCN5 is deleted,
mice die with increasing apoptosis. The mice survive
longer if p53 is also deleted [16]. In addition, BRD7
promotes TCF4-mediated transcription through inter-
action with β-catenin and TCF4. A model has been
proposed whereby BRD7 brings PTP-BL to the Dvl-1
/axin/APC/GSK-3β/β-catenin complex, which results in
enhanced Wnt signaling. This leads to GSK-3β de-
phosphorylation and nuclear translocation of β-catenin
[50]. The BRD7-containing complex positively influences
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with gene activation. However, there are other types of
complexes where BRD7 functions as a repressor. BRD7
can form hSWI-SNF complexes with PRMT5 and PRC2,
which leads to inhibition of the expression of suppressor
of tumorigenicity 7 (ST7) and retinoblastoma-like protein
2 (RBL2) [51]. In addition, reported substrate affinities
range from micromolar to millimolar dissociation con-
stant values [33]. The weak affinities suggest that BCPs
possess a dual function (activation and repression). The
hypothesis further suggests that BCPs form a recruitment
platform or pool for holding different chromatin proteins
and function to activate or repress transcription in a
temporal-spatial pattern. The duality of BCPs depends on
the recruitment of transcription factors and chromatin-
remodelers in response to cellular or environmental sig-
naling. Increasing data concerning the structure and func-
tion of Brds and BCPs will contribute to understanding
the roles of BCPs in normal and abnormal nervous system
development.
Association between BCPs and neurodevelopmental
disorders
Abnormal brain development or injury during the fetal
stage and during childhood leads to neurodevelopmental
and psychiatric disorders. The genetic bases of certain
neurodevelopmental disorders have been known for
decades. Specific genes have been reported to be
associated with neurodevelopmental disorders, but stud-
ies on their functional relevance are still ongoing. BCPs
are involved in embryonic development and neural mal-
formation [52]. Perhaps the most convincing evidence of
the importance of BCPs and their complexes is as
follows: even if the DNA sequences of all genes that dir-
ectly control nervous system development and function
are normal, abnormal modification by mutant or dys-
functional BCPs would result in neurodevelopmental
disorders (Table 1). Thus, we pay particular attention to
BCPs’ roles as TFs, HATs and chromatin-remodeling
modulators in neurodevelopmental disorders.
Among 20 members of the BCP family, BRD2 and
BRWD3 are related to neuronal development as TFs.
During the formation of the nervous system, a tran-
scriptional program precisely determines the number
and types of normal neurons. Precise spatiotemporal
regulation controls neuron proliferation, differentiation
and apoptosis. Although we know that a regulatory net-
work comprising many TFs is required for neuronal de-
velopment, we have only scratched the surface in our
understanding of this process. Neurodevelopmental
disorders show high genetic heterogeneity; therefore, it
is difficult to screen and obtain all related genes thatdirectly influence neural and mental development. In-
creasing evidence implies that BCPs are involved in
neural development. More than 20 members of the BCP
family have been identified as TFs. Here, we use the
roles of BRD2 and BRWD3 in neurodevelopmental
disorders as examples (Table 1).
BRD2 (also called RING3 and Fsrg1) is an important
transcriptional modulator that is expressed in brain
vesicles, the neural tube, the spinal cord and dorsal root
ganglia. At the cellular level, BRD2 is localized to the
nucleus in proliferating cells and to the cytoplasm in
differentiating neuronal precursors [53]. BRD2−/− mice
deviate from normal developmental programs at embry-
onic day 9.0 (E9.0), and die at E11.5, with a smaller em-
bryonic size and neural tube defects (NTDs) [54,55]
(Table 1). The NTDs appear as exencephaly of the hind-
brain. The causal mechanism between BRD2 and NTDs
remains poorly understood. BRD2 is implicated in the
regulation of cellular events, including growth, pro-
liferation, differentiation, and apoptosis. Several asso-
ciated proteins were identified as forming a BRD2
complex using Brd2 rabbit polyclonal immune-affinity
chromatography. Among them, BRD2 combines with
E2F to regulate cell cycle by binding to the cyclin A pro-
moter [56]. In addition, BRD2 is the constituent of TFIID
and SWI/SNF complexes. The available evidence sug-
gests that BRD2 plays an essential role as an integrator
of transcription and chromatin structure during mam-
malian embryogenesis and neurogenesis.
BRWD3 contains two Brds and nine WD repeats. The
WD repeat domains are responsible for interaction with
other proteins to regulate cellular events, such as cell
cycle, signaling transduction, and apoptosis. Truncation
mutants of BRWD3 were identified in the etiology of X-
linked mental retardation during systematic screening of
the X-chromosome coding sequences in 250 families
(Online Mendelian Inheritance in Man (OMIM) ID:
300659) (Table 1). The affected males showed symptoms
of prominent forehead, long face, large cupped ears and
mild-to-moderate intellectual disability [11]. Recently,
we demonstrated that the SNP loci rs7049509 and
rs12689192 near the second Brd domain were linked
with mental retardation [9] and two new mutations in
Brds and WD40 domains, which might be the causes of
mental retardation related to BRWD3 (unpublished
data). Research into the causative mechanism is under-
way. BRWD3 is assumed to be involved in modulation
of the JAK/STAT signaling pathway [57]. Notably, the
mutant phenotype is related with a frame-shift, and the
concomitant loss of a key Brd. Thus, BRWD3 might be
associated with learning and memory.
HATs play important roles in regulating gene
expression during brain development and memory
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neurodevelopmental disorders.
GCN5 is a transcriptional co-activator with HAT activ-
ity [58]. Mutant GCN5 is associated with NTDs. The
structures of GCN5 and its histone substrates are
conserved throughout eukaryotes. GCN5 is indispens-
able for amino acid metabolism, as a component of the
ADA (Adapter) and SPT-ADA-GCN5 acetyltransferase
(SAGA) transcription complexes [59]. These complexes
regulate transcription processes rather than initiation
[16]. The structure of the complex revealed that the
single Brd of GCN5 would preferentially bind acetylated
H4K16. In yeast, GCN5 acetylates other nearby lysine
sites [60]. GCN5 participates in neural and mental devel-
opment. After being treated with a fear-conditioning
stimulus, murine GCN5/KAT2A and acetylation levels
were upregulated within one hour. Deletion of GCN5
leads to early embryonic lethality with cranial NTDs.
Conditional knockout of GCN5 showed that the normal
expression level of GCN5 is critical for neural tube clos-
ure in mice, suggesting that mutations of Gcn5 may be
associated with increasing risk of NTDs in humans [61]
(Table 1). GCN5 acetylates p53 in vitro and in vivo, and
double mutants of Gcn5 and p53 mouse embryos survive
longer than Gcn5 null mice. Deletion of p53 cannot
rescue the embryonic lethality caused by the mutant
of Gcn5. When the HAT activity of GCN5 is abnor-
mal, cranial neural tube closure in mice is defective
[16]. These results reveal that GCN5 is required for
survival, and the HAT activity of GCN5 is critical for
proper neural tube closure. The exact mechanism re-
mains unclear.
Although NTDs are the second commonest disorders
among birth defects in humans, their molecular regula-
tion mechanisms remain poorly understood. Available
evidence suggests that acetylation is involved in the
likely mechanism of the etiology of NTDs. The process
of neural tube closure, including shaping, elevating,
bending, and sealing, is finely regulated. In addition to
the role of GCN5, neural tube closure is related to
acetylation-associated proteins such as CBP, p300, and
Hat1 [62]. Knockouts of p300 and CBP show similar
phenotypes to GCN5, such as embryonic lethality and
NTDs. Consistent with this phenotype, mutations in
CBP (that is, chromosomal translocations, micro-
deletions, and point mutations) are associated with the
congenital developmental disorder, RTS.
As mentioned previously, CBP/p300 is another im-
portant HAT in the BCP family. It is becoming clear that
mutations in CBP/p300 cause 55% of RTS (OMIM ID:
180849), which is characterized by mild to severe mental
retardation, craniofacial defects, short stature, skeletal
abnormalities, broad big toes, and broad thumbs[14,15,63] (Table 1). This syndrome is relatively common,
accounting for 1 in 300 patients with mental retardation.
Haploinsufficiency of CBP probably contributes to RTS in
humans. Mutations of both the PHD finger and Brds have
been identified in RTS patients. In mice, heterozygous de-
letion or truncation of CBP produced a phenotype resem-
bling RTS [15]. Mutations of CBP (Y1175C, E1278K and
R1379P) are associated with RTS, again suggesting the im-
portance of HAT activity [64]. In addition, abnormal CBP/
p300 can be found in progressive neurodegenerative
diseases, such as FRX, myotonic dystrophy, and X-linked
spinal and bulbar muscular atrophy [65]. FRX (OMIM ID:
300624) patients usually suffer from learning disabilities,
macroorchidism, seizures, anxiety, mood disturbance, and
attention problems. In some cases, individuals display aut-
istic symptoms, including poor eye contact, shyness, self-
talk, hand flapping, and hand biting. In line with their
similar physical symptoms to mental retardation, the
affected males present with more typical physical features,
such as prominent ears, macrocephaly, a long face, and a
high arched palate [66].
CBP and p300 are also implicated in memory forma-
tion. P300 of mice is crucial for long-term memory and
learning in a histone acetylation-dependent manner.
Long-term memory is impaired in CBP knockdown
mice, whereas short-term memory is not affected [67]. If
the HAT activity of CBP is abolished, long-term memory
is impaired, but short-term memory is not affected. The
learning ability of mice could be improved after treat-
ment with HDAC inhibitors of the CREB1/CBP com-
plex. Interestingly, long-term memory can also be
rescued with HDACs inhibitors [68,69]. Such studies
have illustrated the critical roles of HAT activity of BCPs
for long-term memory and synaptic plasticity. Therefore,
members of the BCP family with HAT activity regulate
transcription by acting as a recruiting platform and
through their HAT function. Thus, their mutations may
influence transcriptional regulation in two ways: by
disrupting the recruiting process and by preventing
chromatin remodeling. Together with the properties
discussed earlier, at the cellular level, the events leading
to the processes of normal or abnormal neurode-
velopment, such as cell proliferation, differentiation,
survival and polarity may be influenced by acetylation/
deacetylation homeostasis events mediated by these spe-
cial BCPs. At a mechanistic level, intensive research on
members of complexes and downstream genes will be
helpful in providing clues to the underlying causes of
neurodevelopmental disorders.
BCPs also function beyond their main role as
transcriptional modulators and enzymes. Some BCPs
are associated with neurodevelopmental disorders as
chromatin-remodeling modulators.
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affect aspects of chromatin remodeling, in addition to
transcriptional regulation, such as increasing the effi-
ciency of chromatin assembly and modulation, DNA
replication, DNA repair/recombination, and chromo-
somal alteration. The function of chromosome remodel-
ing appears to be different from that of transcription
regulation [70]. The SWI/SNF complex was first identi-
fied as a chromatin-remodeling modulator that remodels
and increases access of transcription factors to nucleo-
somes [71,72]. Abnormal compositions of the SWI/SNF
complex are involved in α-thalassemia mental retardation,
with patients displaying common characteristics, such as
severe cognitive delay, α-thalassemia, facial dysmorphism,
microcephaly, skeletal and genital abnormalities, and se-
vere neonatal hypotonia [73,74]. The null and dominant-
negative gene mutations exhibit defects of the peripheral
nervous system in adults, homeotic transformations, and
decreased viability [75].
WSTF including the nucleosome assembly complex
(WINAC) is another SWI/SNF-type complex that has
ATP-dependent chromatin-remodeling activity. It
interacts with the vitamin D receptor (VDR) through the
Williams syndrome transcription factor (WSTF, also
named bromodomain adjacent zinc finger, BAZ1B).
WINAC is a key complex for repressing and activating
transcription [76], and is required to enable DNA repli-
cation through highly condensed regions of chromatin
[77]. The BAZ1B protein contains a Brd, a PHD-type
zinc finger motif, a WAKZ motif, and a leucine-rich hel-
ical domain (Figure 1). BAZ1B is ubiquitously expressed
in both adult and fetal tissues, such as limb buds, tail
and brain from around E11.5 in the mouse embryo [7].
It is also expressed strongly in the cranial neural crest-
derived mesenchyme, which drives facial morphogenesis.
Phosphorylation of BAZ1B in a MAPK-dependent man-
ner is important to maintain the WINAC complex as-
sembly [76]. BAZ1B has been previously identified as
contributing to WS [78] (Table 1). Total deletion was
detected in 50 of 50 WS individuals using fluorescence
in situ hybridization analysis. WS (OMIM ID: 194050) is
a microdeletion or contiguous gene deletion syndrome
characterized by hemizygous deletion of 1.5 to 1.8 Mb
on chromosome 7q11.23 [78]. The frequency of WS is
estimated to be 1 in 10,000. Subjects with WS show typ-
ical craniofacial dysmorphology (a small upturned nose
with a flat nasal bridge, mandibular hypoplasia, mal-
occlusion, bi-temporal narrowing and prominent fore-
head), supravalvular aortic stenosis, multiple peripheral
pulmonary arterial stenosis, statural deficiency, infantile
hypocalcemia and a distinct cognitive profile with mild
mental retardation [79,80]. The patients suffer from spe-
cific cognitive deficits, including poor visual-motor inte-
gration and attention deficit. In terms of molecularpathogenesis, mutations of BAZ1B and dysfunction of
WINAC contribute to WS [5]. The phosphorylation of
Ser-158 in the WSTF/Acf1/cbpq46 (WAC) domain is es-
sential for maintaining the association between BAZ1B
and core BAF complex components, thereby maintaining
the ATPase activity of WINAC. As a sensor, BAZ1B can
turn on its chromatin-remodeling activity in response to
intracellular signaling [81]. DNA sequence mutations or
abnormal modification would disrupt the regulatory
complex. These studies might support the view that a
chromatin remodeler, such as WINAC, plays a key role
in the development of nervous systems and the patho-
physiology of WS (Table 1).
Deregulation of methylation and BCPs may alter
complex networks of gene expression and brain
function, contributing to neurodevelopmental
disorders.
Brain development is a complicated process, involving
neuron proliferation, differentiation, migration, communi-
cation, and apoptosis. Genetic deficits and negative envir-
onmental exposures may lead to abnormal neurological
development. The characteristics of neurodevelopmental
disorders strongly coincide with the traits of dysfunctional
epigenetic modification at the chromatin level, alone or in
combination. Here, we use Rett syndrome (OMIM ID:
312750) as an example to elucidate the contribution of ab-
errant methylation and dysfunction of BCPs to
neurodevelopmental disorders.
Rett syndrome, a progressive childhood neurodeve-
lopmental disorder, is characterized by stereotypies and
mental retardation, and autistic behavior in females. The
affected individuals show neurodevelopmental defects,
such as common hand movements, aberrant gait, and
seizures [82]. Rett syndrome occurs in 1 in 10,000 to
15,000 births and is caused by mutations in the methyl
CpG binding protein 2 (MeCP2) gene [83]. Most patients
have heterozygous mutations in MeCP2. If MeCP2 is
heterozygous in mice, the female also exhibits behavioral
symptoms. If totally deleted, the mice show severe neuro-
logical symptoms [84]. Although MeCP2 was discovered
about 20 years ago, we still have limited information about
its molecular function. On the one hand, MeCP2 select-
ively binds CpG dinucleotides in the mammalian genome,
mediating transcriptional repression through interaction
with a chromatin-remodeling complex. The SWI/SNF
complex can be recruited by MeCP2 to heterochromatic
foci in living mouse cells in a DNA methylation-
dependent manner. The interaction between ATRX and
MeCP2 may control expression of MeCP2-binding genes.
When the MeCP2-ATRX interaction is disrupted, patho-
logical changes could be identified in a number of
X-linked mental retardations, including Rett syndrome
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transcriptional activator. The exact mechanism of MeCP2
action remains unclear as it acts as a repressor or an acti-
vator, depending on its interacting protein partners.
MeCP2 regulates the brain-derived neurotrophic factor
gene (Bdnf) in resting neurons. Overexpression of Bdnf
can rescue a subset of RTS-like phenotypes [86]. In sum-
mary, increasing data suggest that MeCP2 acts as a tran-
scriptional modulator, repressing genes by binding to
methylated CpG DNA or activating genes through
chromatin reorganization. Further research is required to
understand the molecular pathogenesis of neurode-
velopmental disorders based upon the network created by
genetic determination and epigenetic modification.
Conclusions
The growing number of identified BCPs and the links
between some of these members and neurodeve-
lopmental disorders underscore the importance of this
class of proteins. BCPs, which are ubiquitous and evolu-
tionarily conserved, play pivotal roles in chromatin
modifications, remodeling, and transcriptional regula-
tion. Remarkably, all HATs contain Brds, but not all
BCPs are HATs. Some of them are now considered as
modulators of chromatin remodeling (such as BAZ1A
and CECR2), while some are transcriptional regulators
(such as BRD2 and BRWD3) (Table 1). Significantly,
some BCP complexes are implicated in basal transcrip-
tional regulation through their Brds or the domains of
their partners, influencing the expressions of a range of
genes. However, many BCPs regulate transcription
through Brds or the particular domains of other TFs that
bind to the promoters of target genes (Figure 1). BCPs
are critical for cellular events; therefore, complicated
phenotypes inevitably result from abnormal genotypes of
BCPs or from their dysfunctional complexes. Neurode-
velopmental disorders associated with BCPs are not
limited to those discussed in this review, for example,
bipolar affective disorder and schizophrenia [87]. Further
studies addressing the continued functional analyses of
each BCP family member are required to better assess
the physiological roles of these proteins.
In general, BCPs bind to target sites through their
Brds, and they regulate transcription together with their
binding partners. BCPs not only ‘read’ the histone code
[88], but also dynamically alter chromatin status [89].
HATs (containing some BCPs) write markers on
nucleosomes, and HDACs erase them from nucleo-
somes, and the Brds of some BCPs read the markers
[90]. Alternatively, some BCPs regulate gene transcrip-
tion through the binding of their partners to target sites.
In the process of hormonal and nutrient regulation,
acetyltransferase complexes containing GCN5 repress
glucose metabolism via GCN5 acetylation of PGC-1.alpha; [91]. The evidence presented in this review does
not represent special cases; there are many other
members of the BCP family that may adopt this model
as modifying enzymes. Many relevant mechanisms
remain to be investigated.
Furthermore, histone acetylation can improve the
memory and learning ability through direct control of
epigenetic suppression of gene expression [92]. This ex-
pectation presents an interesting challenge for future
research concerning the wide variety of BCPs. Although
they are unlikely to restore patients’ intelligence, the
HDAC inhibitors SAHA and trichostatin A exhibit
potential rescue deficits in long-term emotional memory
and recognition memory in animal models of RTS. Thus,
it may be possible to enhance quality of life by improv-
ing social behavior and to ameliorate the cognitive and
motor deficits in neurodegenerative disorders (that is,
Huntington’s, Parkinson’s, and Alzheimer’s diseases).
Although the current inhibitors are not efficient enough
for clinical use because they simply increase HAT activ-
ity, emerging advances highlight the potential of apply-
ing BCPs and chromosome acetylation in treating
neurodevelopmental disorders.
Abbreviations
Ash1: Absent, small, or homeotic disc1; ATAD: ATPase family AAA domain-
containing protein; BAZ1A: Bromodomain adjacent zinc finger, 1A;
BAZ1B: Bromodomain adjacent zinc finger, 1B; BCPs: Bromodomain-
containing proteins; Brd1: The first bromodomain protein gene; Brd2: The
second Brd protein gene; BRM: Brahma; BET: Bromodomain and the extra
terminal domain; BPTF: BRD and PHD finger-containing transcription factor;
Brd: Bromodomain; CBP: CREB-binding protein; DRG: Dorsal root ganglia;
FRX: Fragile X syndrome; HAT domain: Histone acetyltransferase domain;
HDACs: Histone deacetylases; LAP finger: Leukemia-associated-protein finger;
MeCP2: Methyl CpG binding protein 2; MLL: Mixed-lineage leukemia;
NTDs: Neural tube defects; OMIM: Online Mendelian Inheritance in Man;
PBAF: Polybromo BRG1-associated factor; PCAF: P300/CREB-binding protein-
associated factor; PDE-4: Phospodiesterase-4; P-TEFb: Positive transcription
elongation factor b; RTS: Rubinstein-Taybi syndrome; SAGA: Spt-Ada-Gcn5
acetyltransferase; SAHA: Suberoylanilide hydroxamic acid; SNP: Single
nucleotide polymorphism; TAF1: TATA-binding protein-associated factor-1;
TAZ: Transcription adaptor putative zinc finger; TFs: Transcription factors;
Tg: Transgenic; TPA: Tetradecanoyl phorbol acetate; VDR: Vitamin D receptor;
VPA: Valproic acid; WD: Tryptophan-aspartate; WS: Williams syndrome;
TFIID: transcription initiation factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JL, GZ and XG made substantial contributions to design of this study, and JL
drafted and manuscript, and GZ and XG revised the manuscript. All authors
contributed to writing the manuscript. All authors read and approved the
final manuscript.
Authors’ information
JL focuses on developmental biology and pathogenesis of complicated
diseases. Recently, his laboratory has identified SNP loci that are positively
associated with mental retardation in the Qinba mountain region, northwest
China. Both loci rs7049509 and rs12689192 are near the second Brd domain
in the BRWD3 gene. After investigating the functional domains and
phosphorylation sites of BRWD3, the group is currently studying the
molecular mechanism of neurodevelopment based upon BRWD3. GZ is a full
professor, the director of Key Laboratory of Resource Biology and
Li et al. Journal of Neurodevelopmental Disorders 2013, 5:4 Page 9 of 11
http://www.jneurodevdisorders.com/content/5/1/4Biotechnology in western China. XG is a full professor, and the vice-director
of the Institute of Population and Health. Since its inception in 1995, the
Institute of Population and Health has been devoted to the study of
neurodevelopmental disorders, such as mental retardation and Fragile X
syndrome. The authors’ research teams have carried out investigations on
the pathogenesis of neurodevelopmental disorders in the Qinba mountain
area, where the incidence is about 3%. In addition to environmental factors,
genetic deficits are critical. Susceptible loci and several genes have been
identified using gene scanning methods.
Acknowledgements
Preparation of this review was financially supported by grants from the
National Natural Science Foundation of China (31071103 to XC Gao), and the
Western Resource Biology and Modern Biological Technology Lab Open
Foundation (ZS11005 and 11JS094 to JL Li).
Author details
1Key Laboratory of Resource Biology and Biotechnology in Western China,
Ministry of Education, College of Life Science, Northwest University, Xi’an
710069, People’s Republic of China. 2Institute of Population and Health,
College of Life Science, Northwest University, Xi’an 710069, People’s Republic
of China. 3Current address: Taibai Road 229#, Xi’an 710069, People’s Republic
of China.
Received: 13 June 2012 Accepted: 25 January 2013
Published: 20 February 2013
References
1. Silva AJ, Ehninger D: Adult reversal of cognitive phenotypes in
neurodevelopmental disorders. J Neurodev Disord 2009, 1:150–157.
2. van Loo KM, Martens GJ: Genetic and environmental factors in complex
neurodevelopmental disorders. Curr Genomics 2007, 8:429–444.
3. Weigel AV, Simon B, Tamkun MM, Krapf D: Ergodic and nonergodic
processes coexist in the plasma membrane as observed by single-
molecule tracking. Proc Natl Acad Sci U S A 2011, 108:6438–6443.
4. Kaufman L, Ayub M, Vincent JB: The genetic basis of non-syndromic
intellectual disability: a review. J Neurodev Disord 2010, 2:182–209.
5. Bochar DA, Savard J, Wang W, Lafleur DW, Moore P, Cote J, Shiekhattar R: A
family of chromatin remodeling factors related to Williams syndrome
transcription factor. Proc Natl Acad Sci U S A 2000, 97:1038–1043.
6. Jones MH, Hamana N, Nezu J, Shimane M: A novel family of
bromodomain genes. Genomics 2000, 63:40–45.
7. Kitagawa H, Fujiki R, Yoshimura K, Mezaki Y, Uematsu Y, Matsui D, Ogawa S,
Unno K, Okubo M, Tokita A, Nakagawa T, Ito T, Ishimi Y, Nagasawa H,
Matsumoto T, Yanagisawa J, Kato S: The chromatin-remodeling complex
WINAC targets a nuclear receptor to promoters and is impaired in
Williams syndrome. Cell 2003, 113:905–917.
8. Cavalleri GL, Walley NM, Soranzo N, Mulley J, Doherty CP, Kapoor A,
Depondt C, Lynch JM, Scheffer IE, Heils A, Gehrmann A, Kinirons P, Gandhi
S, Satishchandra P, Wood NW, Anand A, Sander T, Berkovic SF, Delanty N,
Goldstein DB, Sisodiya SM: A multicenter study of BRD2 as a risk factor for
juvenile myoclonic epilepsy. Epilepsia 2007, 48:706–712.
9. Li J, Li L, Xing L, Zhang M, Yang X, Zheng Z, Li J, Zhang F, Gao X:
Association of BRWD3 gene with mental retardation in Qin-ba
mountains region. Journal of Northwest University(Natural Science Edition)
2012, 42:961–965.
10. Kuwano Y, Kamio Y, Kawai T, Katsuura S, Inada N, Takaki A, Rokutan K:
Autism-associated gene expression in peripheral leucocytes commonly
observed between subjects with autism and healthy women having
autistic children. PLoS One 2011, 6:e24723.
11. Field M, Tarpey PS, Smith R, Edkins S, O’Meara S, Stevens C, Tofts C, Teague
J, Butler A, Dicks E, Barthorpe S, Buck G, Cole J, Gray K, Halliday K, Hills K,
Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson
D, Shepherd R, Small A, Varian J, West S, Widaa S, Mallya U, Wooster R, et al:
Mutations in the BRWD3 gene cause X-linked mental retardation
associated with macrocephaly. Am J Hum Genet 2007, 81:367–374.
12. Tarpey PS, Smith R, Pleasance E, Whibley A, Edkins S, Hardy C, O’Meara S,
Latimer C, Dicks E, Menzies A, Stephens P, Blow M, Greenman C, Xue Y,
Tyler-Smith C, Thompson D, Gray K, Andrews J, Barthorpe S, Buck G, Cole J,
Dunmore R, Jones D, Maddison M, Mironenko T, Turner R, Turrell K, Varian J,
West S, Widaa S, et al: A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet 2009,
41:535–543.
13. Banting GS, Barak O, Ames TM, Burnham AC, Kardel MD, Cooch NS,
Davidson CE, Godbout R, McDermid HE, Shiekhattar R: CECR2, a protein
involved in neurulation, forms a novel chromatin remodeling complex
with SNF2L. Hum Mol Genet 2005, 14:513–524.
14. Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M,
Tommerup N, van Ommen GJ, Goodman RH, Peters DJ, et al: Rubinstein-
Taybi syndrome caused by mutations in the transcriptional co-activator
CBP. Nature 1995, 376:348–351.
15. Roelfsema JH, White SJ, Ariyurek Y, Bartholdi D, Niedrist D, Papadia F, Bacino
CA, den Dunnen JT, van Ommen GJ, Breuning MH, Hennekam RC, Peters
DJ: Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in
both the CBP and EP300 genes cause disease. Am J Hum Genet 2005,
76:572–580.
16. Bu P, Evrard YA, Lozano G, Dent SY: Loss of Gcn5 acetyltransferase activity
leads to neural tube closure defects and exencephaly in mouse
embryos. Mol Cell Biol 2007, 27:3405–3416.
17. Van Houdt JK, Nowakowska BA, Sousa SB, van Schaik BD, Seuntjens E,
Avonce N, Sifrim A, Abdul-Rahman OA, van den Boogaard MJ, Bottani A:
Heterozygous missense mutations in SMARCA2 cause Nicolaides-
Baraitser syndrome. Nat Genet 2012, 44:445–449. S1.
18. Tsurusaki Y, Okamoto N, Ohashi H, Kosho T, Imai Y, Hibi-Ko Y, Kaname T,
Naritomi K, Kawame H, Wakui K, Fukushima Y, Homma T, Kato M, Hiraki Y,
Yamagata T, Yano S, Mizuno S, Sakazume S, Ishii T, Nagai T, Shiina M, Ogata
K, Ohta T, Niikawa N, Miyatake S, Okada I, Mizuguchi T, Doi H, Saitsu H,
Miyake N, et al: Mutations affecting components of the SWI/SNF complex
cause Coffin-Siris syndrome. Nat Genet 2012, 44:376–378.
19. Makino S, Kaji R, Ando S, Tomizawa M, Yasuno K, Goto S, Matsumoto S,
Tabuena MD, Maranon E, Dantes M, Lee LV, Ogasawara K, Tooyama I, Akatsu
H, Nishimura M, Tamiya G: Reduced neuron-specific expression of the
TAF1 gene is associated with X-linked dystonia-parkinsonism. Am J Hum
Genet 2007, 80:393–406.
20. Peserico A, Simone C: Physical and functional HAT/HDAC interplay
regulates protein acetylation balance. J Biomed Biotechnol 2011,
2011:1–10.
21. Jenuwein T, Allis CD: Translating the histone code. Science 2001,
293:1074–1080.
22. Jeanmougin F, Wurtz JM, Le Douarin B, Chambon P, Losson R: The
bromodomain revisited. Trends Biochem Sci 1997, 22:151–153.
23. Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM: Structure and
ligand of a histone acetyltransferase bromodomain. Nature 1999,
399:491–496.
24. Zeng L, Zhou MM: Bromodomain: an acetyl-lysine binding domain.
FEBS Lett 2002, 513:124–128.
25. Nakamura Y, Umehara T, Nakano K, Jang MK, Shirouzu M, Morita S, Uda-
Tochio H, Hamana H, Terada T, Adachi N, Matsumoto T, Tanaka A, Horikoshi
M, Ozato K, Padmanabhan B, Yokoyama S: Crystal structure of the human
BRD2 bromodomain: insights into dimerization and recognition of
acetylated histone H4. J Biol Chem 2007, 282:4193–4201.
26. Huang H, Zhang J, Shen W, Wang X, Wu J, Shi Y: Solution structure of the
second bromodomain of Brd2 and its specific interaction with
acetylated histone tails. BMC Struct Biol 2007, 7:57.
27. Umehara T, Nakamura Y, Jang MK, Nakano K, Tanaka A, Ozato K,
Padmanabhan B, Yokoyama S: Structural basis for acetylated histone H4
recognition by the human BRD2 bromodomain. J Biol Chem 2010,
285:7610–7618.
28. Umehara T, Nakamura Y, Wakamori M, Ozato K, Yokoyama S, Padmanabhan
B: Structural implications for K5/K12-di-acetylated histone H4 recognition
by the second bromodomain of BRD2. FEBS Lett 2010, 584:3901–3908.
29. Kalkhoven E: CBP and p300: HATs for different occasions. Biochem
Pharmacol 2004, 68:1145–1155.
30. Ragvin A, Valvatne H, Erdal S, Arskog V, Tufteland KR, Breen K, OYan AM,
Eberharter A, Gibson TJ, Becker PB, Aasland R: Nucleosome binding by the
bromodomain and PHD finger of the transcriptional cofactor p300. J Mol
Biol 2004, 337:773–788.
31. Bycroft M: Recognition of non-methyl histone marks. Curr Opin Struct Biol
2011, 21:761–766.
32. Zeng L, Zhang Q, Li S, Plotnikov AN, Walsh MJ, Zhou MM: Mechanism and
regulation of acetylated histone binding by the tandem PHD finger of
DPF3b. Nature 2010, 466:258–262.
Li et al. Journal of Neurodevelopmental Disorders 2013, 5:4 Page 10 of 11
http://www.jneurodevdisorders.com/content/5/1/433. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-
Lovejoy D, Felletar I, Volkmer R, Muller S, Pawson T, Gingras AC, Arrowsmith
CH, Knapp S: Histone recognition and large-scale structural analysis of
the human bromodomain family. Cell 2012, 149:214–231.
34. Ruthenburg AJ, Li H, Milne TA, Dewell S, McGinty RK, Yuen M, Ueberheide B,
Dou Y, Muir TW, Patel DJ, Allis CD: Recognition of a mononucleosomal
histone modification pattern by BPTF via multivalent interactions. Cell
2011, 145:692–706.
35. Mujtaba S, He Y, Zeng L, Farooq A, Carlson JE, Ott M, Verdin E, Zhou MM:
Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF
bromodomain. Mol Cell 2002, 9:575–586.
36. Chen J, Ghazawi FM, Li Q: Interplay of bromodomain and histone acetylation
in the regulation of p300-dependent genes. Epigenetics 2010, 5:509–515.
37. Ivanov AV, Peng H, Yurchenko V, Yap KL, Negorev DG, Schultz DC,
Psulkowski E, Fredericks WJ, White DE, Maul GG, Sadofsky MJ, Zhou MM,
Rauscher FJ 3rd: PHD domain-mediated E3 ligase activity directs
intramolecular sumoylation of an adjacent bromodomain required for
gene silencing. Mol Cell 2007, 28:823–837.
38. Borah JC, Mujtaba S, Karakikes I, Zeng L, Muller M, Patel J, Moshkina N,
Morohashi K, Zhang W, Gerona-Navarro G, Hajjar RJ, Zhou MM: A small
molecule binding to the coactivator CREB-binding protein blocks
apoptosis in cardiomyocytes. Chem Biol 2011, 18:531–541.
39. Filippakopoulos P, Picaud S, Fedorov O, Keller M, Wrobel M, Morgenstern O,
Bracher F, Knapp S: Benzodiazepines and benzotriazepines as protein
interaction inhibitors targeting bromodomains of the BET family. Bioorg
Med Chem 2012, 20:1878–1886.
40. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW,
Chandwani R, Marazzi I, Wilson P, Coste H, White J, Kirilovsky J, Rice CM,
Lora JM, Prinjha RK, Lee K, Tarakhovsky A: Suppression of inflammation by
a synthetic histone mimic. Nature 2010, 468:1119–1123.
41. Chung CW, Coste H, White JH, Mirguet O, Wilde J, Gosmini RL, Delves C,
Magny SM, Woodward R, Hughes SA, Boursier EV, Flynn H, Bouillot AM,
Bamborough P, Brusq JM, Gellibert FJ, Jones EJ, Riou AM, Homes P, Martin
SL, Uings IJ, Toum J, Clement CA, Boullay AB, Grimley RL, Blandel FM,
Prinjha RK, Lee K, Kirilovsky J, Nicodeme E: Discovery and characterization
of small molecule inhibitors of the BET family bromodomains. J Med
Chem 2011, 54:3827–3838.
42. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E,
Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan
TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC,
Anderson KC, Kung AL, Bradner JE, Mitsiades CS: BET bromodomain inhibition
as a therapeutic strategy to target c-Myc. Cell 2011, 146:904–917.
43. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM,
Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y,
Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N,
French CA, Wiest O, Kung AL, Knapp S, Bradner JE: Selective inhibition of
BET bromodomains. Nature 2010, 468:1067–1073.
44. Denis GV: Duality in bromodomain-containing protein complexes. Front
Biosci 2001, 6:D849–D852.
45. Bannister AJ, Kouzarides T: The CBP co-activator is a histone
acetyltransferase. Nature 1996, 384:641–643.
46. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y: The
transcriptional coactivators p300 and CBP are histone acetyltransferases.
Cell 1996, 87:953–959.
47. Pugh BF: HATs off to PIC assembly. Mol Cell 2006, 23:776–777.
48. Mujtaba S, He Y, Zeng L, Yan S, Plotnikova O, Sachchidanand, Sanchez R,
Zeleznik-Le NJ, Ronai Z, Zhou MM: Structural mechanism of the
bromodomain of the coactivator CBP in p53 transcriptional activation.
Mol Cell 2004, 13:251–263.
49. Mantovani F, Drost J, Voorhoeve PM, Del Sal G, Agami R: Gene regulation
and tumor suppression by the bromodomain-containing protein BRD7.
Cell Cycle 2010, 9:2777–2781.
50. Kim S, Lee J, Park J, Chung J: BP75, bromodomain-containing M(r) 75,000
protein, binds dishevelled-1 and enhances Wnt signaling by inactivating
glycogen synthase kinase-3 beta. Cancer Res 2003, 63:4792–4795.
51. Tae S, Karkhanis V, Velasco K, Yaneva M, Erdjument-Bromage H, Tempst P,
Sif S: Bromodomain protein 7 interacts with PRMT5 and PRC2, and is
involved in transcriptional repression of their target genes. Nucleic Acids
Res 2011, 39:5424–5438.
52. Denis GV: Bromodomain coactivators in cancer, obesity, type 2 diabetes,
and inflammation. Discov Med 2010, 10:489–499.53. Crowley T, Brunori M, Rhee K, Wang X, Wolgemuth DJ: Change in nuclear-
cytoplasmic localization of a double-bromodomain protein during
proliferation and differentiation of mouse spinal cord and dorsal root
ganglia. Brain Res Dev Brain Res 2004, 149:93–101.
54. Shang E, Wang X, Wen D, Greenberg DA, Wolgemuth DJ: Double
bromodomain-containing gene Brd2 is essential for embryonic
development in mouse. Dev Dyn 2009, 238:908–917.
55. Gyuris A, Donovan DJ, Seymour KA, Lovasco LA, Smilowitz NR, Halperin AL,
Klysik JE, Freiman RN: The chromatin-targeting protein Brd2 is required
for neural tube closure and embryogenesis. Biochim Biophys Acta 2009,
1789:413–421.
56. Denis GV, McComb ME, Faller DV, Sinha A, Romesser PB, Costello CE:
Identification of transcription complexes that contain the double
bromodomain protein Brd2 and chromatin remodeling machines. J
Proteome Res 2006, 5:502–511.
57. Muller P, Kuttenkeuler D, Gesellchen V, Zeidler MP, Boutros M: Identification
of JAK/STAT signalling components by genome-wide RNA interference.
Nature 2005, 436:871–875.
58. Brownell JE, Zhou J, Ranalli T, Kobayashi R, Edmondson DG, Roth SY, Allis
CD: Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p
linking histone acetylation to gene activation. Cell 1996, 84:843–851.
59. Wang L, Liu L, Berger SL: Critical residues for histone acetylation by Gcn5,
functioning in Ada and SAGA complexes, are also required for
transcriptional function in vivo. Genes Dev 1998, 12:640–653.
60. Owen DJ, Ornaghi P, Yang JC, Lowe N, Evans PR, Ballario P, Neuhaus D,
Filetici P, Travers AA: The structural basis for the recognition of acetylated
histone H4 by the bromodomain of histone acetyltransferase gcn5p.
EMBO J 2000, 19:6141–6149.
61. Lin W, Zhang Z, Chen CH, Behringer RR, Dent SY: Proper Gcn5 histone
acetyltransferase expression is required for normal anteroposterior
patterning of the mouse skeleton. Dev Growth Differ 2008, 50:321–330.
62. Dutnall RN, Tafrov ST, Sternglanz R, Ramakrishnan V: Structure of the
histone acetyltransferase Hat1: a paradigm for the GCN5-related N-
acetyltransferase superfamily. Cell 1998, 94:427–438.
63. Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A: Histone
acetylation and disease. Cell Mol Life Sci 2001, 58:728–736.
64. Murata T, Kurokawa R, Krones A, Tatsumi K, Ishii M, Taki T, Masuno M,
Ohashi H, Yanagisawa M, Rosenfeld MG, Glass CK, Hayashi Y: Defect of
histone acetyltransferase activity of the nuclear transcriptional
coactivator CBP in Rubinstein-Taybi syndrome. Hum Mol Genet 2001,
10:1071–1076.
65. Paulson HL, Fischbeck KH: Trinucleotide repeats in neurogenetic
disorders. Annu Rev Neurosci 1996, 19:79–107.
66. Berry-Kravis E, Knox A, Hervey C: Targeted treatments for fragile X
syndrome. J Neurodev Disord 2011, 3:193–210.
67. Alarcon JM, Malleret G, Touzani K, Vronskaya S, Ishii S, Kandel ER, Barco A:
Chromatin acetylation, memory, and LTP are impaired in CBP+/− mice: a
model for the cognitive deficit in Rubinstein-Taybi syndrome and its
amelioration. Neuron 2004, 42:947–959.
68. Urdinguio RG, Sanchez-Mut JV, Esteller M: Epigenetic mechanisms in
neurological diseases: genes, syndromes, and therapies. Lancet Neurol
2009, 8:1056–1072.
69. Kramer JM, van Bokhoven H: Genetic and epigenetic defects in mental
retardation. Int J Biochem Cell Biol 2009, 41:96–107.
70. Fyodorov DV, Kadonaga JT: The many faces of chromatin remodeling:
SWItching beyond transcription. Cell 2001, 106:523–525.
71. Khavari PA, Peterson CL, Tamkun JW, Mendel DB, Crabtree GR: BRG1
contains a conserved domain of the SWI2/SNF2 family necessary for
normal mitotic growth and transcription. Nature 1993, 366:170–174.
72. Laurent BC, Treich I, Carlson M: Role of yeast SNF and SWI proteins in
transcriptional activation. Cold Spring Harb Symp Quant Biol 1993,
58:257–263.
73. Gibbons RJ, Picketts DJ, Villard L, Higgs DR: Mutations in a putative global
transcriptional regulator cause X-linked mental retardation with alpha-
thalassemia (ATR-X syndrome). Cell 1995, 80:837–845.
74. Gibbons RJ, Higgs DR: Molecular-clinical spectrum of the ATR-X
syndrome. Am J Med Genet 2000, 97:204–212.
75. Elfring LK, Daniel C, Papoulas O, Deuring R, Sarte M, Moseley S, Beek SJ,
Waldrip WR, Daubresse G, DePace A, Kennison JA, Tamkun JW: Genetic
analysis of brahma: the Drosophila homolog of the yeast chromatin
remodeling factor SWI2/SNF2. Genetics 1998, 148:251–265.
Li et al. Journal of Neurodevelopmental Disorders 2013, 5:4 Page 11 of 11
http://www.jneurodevdisorders.com/content/5/1/476. Oya H, Yokoyama A, Yamaoka I, Fujiki R, Yonezawa M, Youn MY, Takada I,
Kato S, Kitagawa H: Phosphorylation of Williams syndrome transcription
factor by MAPK induces a switching between two distinct chromatin
remodeling complexes. J Biol Chem 2009, 284:32472–32482.
77. Collins N, Poot RA, Kukimoto I, Garcia-Jimenez C, Dellaire G, Varga-Weisz PD:
An ACF1-ISWI chromatin-remodeling complex is required for DNA
replication through heterochromatin. Nat Genet 2002, 32:627–632.
78. Lu X, Meng X, Morris CA, Keating MT: A novel human gene, WSTF, is
deleted in Williams syndrome. Genomics 1998, 54:241–249.
79. Perez Jurado AL: Williams-Beuren syndrome: a model of recurrent
genomic mutation. Horm Res 2003, 59(Suppl 1):106–113.
80. Pober BR: Williams-Beuren syndrome. N Engl J Med 2010, 362:239–252.
81. Kitagawa H, Fujiki R, Yoshimura K, Oya H, Kato S: Williams syndrome is an
epigenome-regulator disease. Endocr J 2011, 58:77–85.
82. Zoghbi HY: Postnatal neurodevelopmental disorders: meeting at the
synapse? Science 2003, 302:826–830.
83. Kavalali ET, Nelson ED, Monteggia LM: Role of MeCP2, DNA methylation, and
HDACs in regulating synapse function. J Neurodev Disord 2011, 3:250–256.
84. Guy J, Hendrich B, Holmes M, Martin JE, Bird A: A mouse Mecp2-null
mutation causes neurological symptoms that mimic Rett syndrome. Nat
Genet 2001, 27:322–326.
85. Nan X, Hou J, Maclean A, Nasir J, Lafuente MJ, Shu X, Kriaucionis S, Bird A:
Interaction between chromatin proteins MECP2 and ATRX is disrupted
by mutations that cause inherited mental retardation. Proc Natl Acad Sci
U S A 2007, 104:2709–2714.
86. Zachariah RM, Rastegar M: Linking epigenetics to human disease and Rett
syndrome: the emerging novel and challenging concepts in MeCP2
research. Neural Plast 2012, 2012:415825.
87. Severinsen JE, Bjarkam CR, Kiaer-Larsen S, Olsen IM, Nielsen MM,
Blechingberg J, Nielsen AL, Holm IE, Foldager L, Young BD, Muir WJ,
Blackwood DH, Corydon TJ, Mors O, Børglum AD: Evidence implicating
BRD1 with brain development and susceptibility to both schizophrenia
and bipolar affective disorder. Mol Psychiatry 2006, 11:1126–1138.
88. Glatt S, Alfieri C, Muller CW: Recognizing and remodeling the nucleosome.
Curr Opin Struct Biol 2011, 21:335–341.
89. Matangkasombut O, Buratowski RM, Swilling NW, Buratowski S:
Bromodomain factor 1 corresponds to a missing piece of yeast TFIID.
Genes Dev 2000, 14:951–962.
90. Muller S, Filippakopoulos P, Knapp S: Bromodomains as therapeutic
targets. Expert Rev Mol Med 2011, 13:e29.
91. Lerin C, Rodgers JT, Kalume DE, Kim SH, Pandey A, Puigserver P: GCN5
acetyltransferase complex controls glucose metabolism through
transcriptional repression of PGC-1alpha. Cell Metab 2006, 3:429–438.
92. Schaefer A, Tarakhovsky A, Greengard P: Epigenetic mechanisms of mental
retardation. Prog Drug Res 2011, 67:125–146.
doi:10.1186/1866-1955-5-4
Cite this article as: Li et al.: Development of neurodevelopmental
disorders: a regulatory mechanism involving bromodomain-containing
proteins. Journal of Neurodevelopmental Disorders 2013 5:4.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
